Neuralstem reports plan to price public offering of its common shares

Bookrunner Aegis will help raise funds for general corporate purposes

By Devika Patel

Knoxville, Tenn., Sept. 13 - Neuralstem, Inc. said it plans to conduct a public offering of common stock. Aegis Capital Corp. is the bookrunner.

Proceeds will be used for general corporate purposes, including research and development expenditures, working capital, capital expenditures, clinical trial expenditures and other general corporate purposes.

Based in Rockville, Md., Neuralstem develops technologies to transplant human neural stem cells.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.